NanoViricides Announces Promising Results for Measles Treatment in Humanized Animal Study
NanoViricides, Inc. reports a significant breakthrough with its lead drug candidate, NV-387, showing increased survival rates in a lethal measles infection model, highlighting the potential for the first therapeutic option amid rising global measles cases.
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antivirals, has announced promising results for its lead drug candidate, NV-387, in treating measles. In a lethal respiratory infection model using humanized mice, NV-387 increased survival by 130%, from 7.4 to 17 days, with no observed toxicity and dose-dependent efficacy. The drug's mechanism involves mimicking human cell features to bind and neutralize viruses, targeting over 90% of human pathogens.
With global measles cases surging and vaccine coverage declining, the development of NV-387 addresses an urgent need for a therapeutic option. Anil R. Diwan, PhD, highlighted the significance of the findings, stating, "NV-387 is on its way to become the very first drug to treat Measles." This breakthrough could mark a pivotal moment in the fight against measles, especially in regions where vaccine access is limited or declining.
For more details on the study and its implications, visit https://ibn.fm/0nUwO.